Anti-Cancer Drugs

SCI期刊
Anti-Cancer Drugs
中文名称:
抗癌药
期刊缩写:
ANTI-CANCER DRUG
影响因子:
1.8
ISSN:
print: 0959-4973
on-line: 1473-5741
研究领域:
医学-药学
创刊年份:
1990年
h-index:
88
自引率:
0.00%
Gold OA文章占比:
18.89%
原创研究文献占比:
90.04%
SCI收录类型:
Science Citation Index Expanded (SCIE) || Scopus (CiteScore)
期刊介绍英文:
Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
CiteScore:
CiteScoreSJRSNIPCiteScore排名
3.80.4760.360
学科
排名
百分位
大类:Medicine
小类:Pharmacology (medical)
129 / 272
52%
大类:Medicine
小类:Oncology
218 / 404
46%
大类:Pharmacology, Toxicology and Pharmaceutics
小类:Pharmacology
181 / 313
42%
大类:Biochemistry, Genetics and Molecular Biology
小类:Cancer Research
161 / 230
30%
发文信息
中科院SCI期刊分区
大类 小类 TOP期刊 综述期刊
4区 医学
4区 肿瘤学 ONCOLOGY
4区 药学 PHARMACOLOGY & PHARMACY
WOS期刊分区
学科分类
Q3ONCOLOGY
Q3PHARMACOLOGY & PHARMACY
历年影响因子
2015年2.2680
2016年2.3200
2017年1.8690
2018年1.8010
2019年2.2600
2020年2.2480
2021年2.3890
2022年2.3000
2023年1.8000
历年发表
2012年136
2013年127
2014年142
2015年133
2016年134
2017年136
2018年124
2019年144
2020年184
2021年374
2022年244
投稿信息
出版周期:
Monthly
出版语言:
English
出版国家(地区):
UNITED STATES
接受率:
100%
审稿时长:
3 months
出版商:
Lippincott Williams and Wilkins Ltd.
编辑部地址:
LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621

Anti-Cancer Drugs - 最新文献

Surufatinib combined camrelizumab as a valuable third-line rescue therapy for a patient with extensive-stage for small-cell lung cancer: a case report and literature review.

Pub Date : 2024-03-01 DOI: 10.1097/CAD.0000000000001552 Chi Pan, Tao Yu, Li Han, Daxuan Hao, Ming Yang, Lin Li, Laili Chu, Qingtao Ni

Dual targeting of Mcl-1 and Bcl-2 to overcome chemoresistance in cervical and colon cancer.

Pub Date : 2024-03-01 DOI: 10.1097/CAD.0000000000001553 Ling Wang, Changlei Xi, Rong Liu, Tingting Ye, Ning Xiang, Jinfang Deng, Hui Li

Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review.

Pub Date : 2024-03-01 DOI: 10.1097/CAD.0000000000001555 Fernando Salazar González, Cristel Andrea Quiñones Palacios, Alba Manzaneque Gordón, José María Mazarico Gallego, Alba Díaz, Gloria Molas Ferrer
查看全部
免责声明:
本页显示期刊或杂志信息,仅供参考学习,不是任何期刊杂志官网,不涉及出版事务,特此申明。如需出版一切事务需要用户自己向出版商联系核实。若本页展示内容有任何问题,请联系我们,邮箱:info@booksci.cn,我们会认真核实处理。
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信